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Introduction
In the past decade biologics have changed the manage-
ment of juvenile idiopathic arthritis (JIA). Many studies
have evaluated the effectiveness and safety of the avail-
able biologics in JIA. Biological therapy used to be
reserved for the severely ill JIA patients refractory to
conventional therapy. Due to the treatment success of
several biologics, more and more patients with JIA are
now being treated with these drugs. In addition studies
show that some patients may benefit from biologic
therapy early in the disease course. However biologics
are very expensive compared to conventional treat-
ment. From a social-economic view the additional
costs of new interventions should be weighted against
their incremental health benefits compared to standard
care.
Objectives
We studied data on cost-effectiveness of biologics in JIA
and evaluated the existing economic evaluations with
implications for future research.
Methods
We searched Medline, Embase, The Cochrane Library
and The York Centre for Reviews and Dissemination
database for relevant literature.
Results
Current data on costs of biologics in JIA are scarce; five
studies describe the costs of this treatment in JIA. Only
three of these studies compare the costs with the treat-
ment effect. These studies show that biologics are more
costly than other rheumatic drugs but other direct
and indirect treatment costs are reduced due to the
effectiveness of biologics. Considering the economic
pressure on the healthcare system, cost-effectiveness of a
treatment is import factor in clinical practice. Unfortu-
nately data on long-term cost-effectiveness of biologics
or treatment strategies involving biologics are lacking.
Since JIA is a chronic disease emphasis should also be
placed on how biologics effect long-term progression of
disability and translate this in quality-adjust life-years
(QALYs). Cost-utility models compare treatment costs to
effectiveness in QALYs and will be of great interest to
policymakers.
Conclusion
Biologics are expensive compared to other anti-rheumatic
drugs. After evaluating the possible economic models to
study drug costs, we suggest that future research should
provide health economic evidence from usual practice
settings that evaluate the cost-effectiveness of specific
clinical targets in individual patients. Next to studying
cost-effectiveness of biologics in JIA, also long-term cost-
utility should be evaluated. These measurements provide
valuable information on the long-term effect of a treat-
ment from a social-economic perspective.
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